Phenotypic Characterization of Congenital Hyperinsulinism Due to Novel Activating Glucokinase Mutations.

"Duality of Interest. C.L. and Y.Y. are employees of Nanjing AscendRare Pharmaceutical Technology Co. D.D.D.L. has received consulting fees from Zealand Pharma A/S, Crinetics Pharmaceuticals, Hanmi Pharmaceutical, and Eiger Pharma and has received funding/research contracts from Zealand Pharma A/S, Rezolute, Crinetics Pharmaceuticals, Twist, Hanmi Pharmaceutical, and Ultragenyx for studies not included in this manuscript. No other potential conflicts of interest relevant to this article were reported."

"This work was supported by National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases grants R01DK098517 and R01DK056268 to D.D.D.L. and by the University of Pennsylvania Diabetes Research Center National Institute of Health grant P30DK19525."